glp-1 latest use tripled among non-diabetics, reaching $5.8B in 2022 Market Overview: GLP-1 Agonists and

Variants in FTO , the fat-mass and obesity-associated gene, along with GLP1R (the GLP-1 receptor gene that every GLP-1 compound targets), MC4R (a melanocortin receptor tied to satiety and energy balance), and TCF7L2 (a transcription factor linked to glucose homeostasis) describe the metabolic terrain a clinician is prescribing into

Unlike brand-name drugs, compounded versions are not FDA-approved as finished products

Slow dose escalation improves tolerance and minimizes the potential risks

Notably, around two-thirds of volume are users new to any GLP-1 therapy, suggesting that convenience, and lower prices expand the market rather than simply driving switching from injectables